Literature DB >> 21487730

Mild cognitive impairment in Parkinson's disease.

Dag Aarsland1, Kolbjørn Brønnick, Tormod Fladby.   

Abstract

Prospective studies conducted during the last decade have shown that the majority of patients with Parkinson's disease (PD) develop dementia. In addition, using a variety of definitions and methods, more recent research suggests that approximately a quarter of PD patients without dementia have mild cognitive impairment (PD-MCI). Furthermore, several studies have shown that approximately 20% have MCI even at time of diagnosis of PD. The typical cognitive deficits include visuospatial, attentional, and executive deficits, but memory deficits have also been shown. The etiology of PD-MCI is not known, but it is likely that mechanisms known to contribute to dementia in PD (ie, limbic and cortical Lewy bodies, amyloid plaques, and cholinergic deficits) play a role, in addition to dysfunction of dopaminergic frontostriatal circuits. PD-MCI predicts a shorter time to dementia, and preliminary evidence suggests that this is particularly true for posterior cognitive deficits. There are currently no systematic clinical trials in PD-MCI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487730     DOI: 10.1007/s11910-011-0203-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  55 in total

1.  Biomarker promise for Parkinson's disease.

Authors: 
Journal:  Lancet Neurol       Date:  2010-12       Impact factor: 44.182

Review 2.  A systematic review of prevalence studies of dementia in Parkinson's disease.

Authors:  Dag Aarsland; Julia Zaccai; Carol Brayne
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

3.  Cognitive profile of patients with newly diagnosed Parkinson disease.

Authors:  Dino Muslimovic; Bart Post; Johannes D Speelman; Ben Schmand
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

4.  Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.

Authors:  Kolbjørn Brønnick; Guido Alves; Dag Aarsland; Ole-Bjørn Tysnes; Jan Petter Larsen
Journal:  Neuropsychology       Date:  2011-01       Impact factor: 3.295

Review 5.  Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation.

Authors:  Angie A Kehagia; Graham K Murray; Trevor W Robbins
Journal:  Curr Opin Neurobiol       Date:  2010-02-16       Impact factor: 6.627

6.  Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study.

Authors:  Carmen Cristea Janvin; Dag Aarsland; Jan Petter Larsen
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-09       Impact factor: 2.680

7.  White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.

Authors:  Turi O Dalaker; Jan P Larsen; Michael G Dwyer; Dag Aarsland; Mona K Beyer; Guido Alves; Kolbjorn Bronnick; Ole-Bjorn Tysnes; Robert Zivadinov
Journal:  Neuroimage       Date:  2009-06-16       Impact factor: 6.556

8.  Course of cognitive decline in Parkinson's disease: a meta-analysis.

Authors:  Dino Muslimović; Ben Schmand; Johannes D Speelman; Rob J de Haan
Journal:  J Int Neuropsychol Soc       Date:  2007-11       Impact factor: 2.892

9.  Nonlinear decline of mini-mental state examination in Parkinson's disease.

Authors:  Dag Aarsland; Graciela Muniz; Fiona Matthews
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

10.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

Authors:  Thomas Foltynie; Carol E G Brayne; Trevor W Robbins; Roger A Barker
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501

View more
  49 in total

1.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

2.  Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Authors:  G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

Review 3.  Trends and issues in characterizing early cognitive changes in Parkinson's disease.

Authors:  Daniel O Claassen; Scott A Wylie
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

4.  The role of the right dorsolateral prefrontal cortex in the Tower of London task performance: repetitive transcranial magnetic stimulation study in patients with Parkinson's disease.

Authors:  H Srovnalova; R Marecek; R Kubikova; I Rektorova
Journal:  Exp Brain Res       Date:  2012-09-14       Impact factor: 1.972

Review 5.  A Comprehensive Meta-analysis on Short-term and Working Memory Dysfunction in Parkinson's Disease.

Authors:  Ari Alex Ramos; Liana Machado
Journal:  Neuropsychol Rev       Date:  2021-02-01       Impact factor: 7.444

6.  Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.

Authors:  Brenda Hanna-Pladdy; Rajesh Pahwa; Kelly E Lyons
Journal:  J Int Neuropsychol Soc       Date:  2015-04-29       Impact factor: 2.892

7.  Relation between Olfactory Dysfunction and Episodic Verbal Memory in Early Parkinson's Disease.

Authors:  Lütfü Hanoğlu; Hüsniye Aylin Hakyemez; Feriha Özer; Serkan Özben; Sema Demirci; Emel Oğuz Akarsu
Journal:  Noro Psikiyatr Ars       Date:  2014-12-01       Impact factor: 1.339

Review 8.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

9.  Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.

Authors:  Xiumin Liu; Chenkang Wang; Weiwei Liu; Siaoyu Song; Jianing Fu; Toshihiko Hayashi; Kazunori Mizuno; Shunji Hattori; Hitomi Fujisaki; Takashi Ikejima
Journal:  Neurochem Res       Date:  2021-06-07       Impact factor: 3.996

10.  Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients.

Authors:  Maria Teresa Pellecchia; Gabriella Santangelo; Marina Picillo; Rosario Pivonello; Katia Longo; Claudia Pivonello; Carmine Vitale; Marianna Amboni; Anna De Rosa; Marcello Moccia; Roberto Erro; Giuseppe De Michele; Lucio Santoro; Annamaria Colao; Paolo Barone
Journal:  J Neurol       Date:  2012-08-22       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.